Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Retinopathy Of Prematurity Treatment Pipeline Review H2 2016

Friday, October 14, 2016 4:17
% of readers think this story is Fact. Add your two cents.

(Before It's News)


‘Retinopathy Of Prematurity – Pipeline Review, H2 2016’, provides an overview of the Retinopathy Of Prematurity pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinopathy Of Prematurity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued projects.

Request a sample report @

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


- The report provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity 
- The report reviews pipeline therapeutics for Retinopathy Of Prematurity by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Retinopathy Of Prematurity therapeutics and enlists all their major and minor projects 
- The report assesses Retinopathy Of Prematurity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Retinopathy Of Prematurity

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Retinopathy Of Prematurity 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Retinopathy Of Prematurity pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @

Key points in table of content

Table of Contents 2 
List of Tables 4 
List of Figures 4 
Introduction 5 
Global Markets Direct Report Coverage 5 
Retinopathy Of Prematurity Overview 6 
Therapeutics Development 7 
Pipeline Products for Retinopathy Of Prematurity – Overview 7 
Retinopathy Of Prematurity – Therapeutics under Development by Companies 8 
Retinopathy Of Prematurity – Pipeline Products Glance 9 
Late Stage Products 9 
Early Stage Products 10 
Retinopathy Of Prematurity – Products under Development by Companies 11 
Retinopathy Of Prematurity – Companies Involved in Therapeutics Development 12 
Biomar Microbial Technologies 12 
F. Hoffmann-La Roche Ltd. 13 
Retinopathy Of Prematurity – Therapeutics Assessment 14 
Assessment by Monotherapy Products 14 
Assessment by Target 15 
Assessment by Mechanism of Action 17 
Assessment by Route of Administration 19 
Assessment by Molecule Type 21 
Drug Profiles 23 
AP-202 – Drug Profile 23 
Product Description 23 
Mechanism Of Action 23 
R&D Progress 23 
IB-09A0133 – Drug Profile 24 
Product Description 24 
Mechanism Of Action 24 
R&D Progress 24 
R-200 – Drug Profile 25 
Product Description 25 
Mechanism Of Action 25 
R&D Progress 25 
ranibizumab – Drug Profile 26 
Product Description 26 
Mechanism Of Action 26 
R&D Progress 26 
Recombinant Protein for Cancer and Diabetic Retinopathy – Drug Profile 32 
Product Description 32 
Mechanism Of Action 32 
R&D Progress 32 
Retinopathy Of Prematurity – Dormant Projects 33 
Retinopathy Of Prematurity – Discontinued Products 34 
Appendix 35 
Methodology 35 
Coverage 35 
Secondary Research 35 
Primary Research 35 
Expert Panel Validation 35 
Contact Us 35 
Disclaimer 36

List of Tables 
Number of Products under Development for Retinopathy Of Prematurity, H2 2016 7 
Number of Products under Development by Companies, H2 2016 8 
Comparative Analysis by Late Stage Development, H2 2016 9 
Comparative Analysis by Early Stage Development, H2 2016 10 
Products under Development by Companies, H2 2016 11 
Retinopathy Of Prematurity – Pipeline by Biomar Microbial Technologies, H2 2016 12 
Retinopathy Of Prematurity – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 13 
Assessment by Monotherapy Products, H2 2016 14 
Number of Products by Stage and Target, H2 2016 16 
Number of Products by Stage and Mechanism of Action, H2 2016 18 
Number of Products by Stage and Route of Administration, H2 2016 20 
Number of Products by Stage and Molecule Type, H2 2016 22 
Retinopathy Of Prematurity – Dormant Projects, H2 2016 33 
Retinopathy Of Prematurity – Discontinued Products, H2 2016 34

Get this report @

Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.